现代妇产科进展2024，Vol.33Issue(1)：7-11,5.DOI:10.13283/j.cnki.xdfckjz.2024.01.001
二甲双胍与2型糖尿病患者卵巢癌风险及预后关系的meta分析
Meta-analysis of the relationship between metformin and ovarian neoplasms risk and prognosis in patients with type 2 diabetes
摘要
Abstract
Objective:To assess the risk of ovarian neoplasms and oncologic outcomes among patients with type 2 diabetes who underwent treatment with metformin.Methods:We conducted a systematic literature search on PubMed,Embase,Web of Science,SinoMed,VIP,Wanfang,and CNKI.The subject terms employed for retrieval encompassed type 2 diabetes,metformin,ovarian cancer risk,and prognosis.The retrieval timeframe spanned from the incep-tion of the database until February 1,2023.Meta-analysis was performed using Review Manager(RevMan)software version 5.3.Results:A comprehensive analysis was conducted,incorpora-ting a total of 15 studies,all of which were determined to possess a high level of quality based on a mean Newcastle-Ottawa Scale(NOS)score of 7.5.The meta-analysis revealed that the u-tilization of metformin did not exhibit a significant reduction in the incidence of ovarian neo-plasms in patients with type 2 diabetes(HR=0.87,95%CI 0.70～1.10,P=0.24).However,it did demonstrate a notable extension in overall survival(OS)(HR=0.51,95%CI 0.35～0.75,P=0.0006)and progression-free survival(PFS)(HR=0.37,95%CI 0.27～0.51,P<0.00001).Conclusion:The results of the study revealed that although metformin did not exhib-it a decrease in the occurrence of ovarian cancer,it may enhance both overall survival and pro-gression-free survival in individuals diagnosed with type 2 diabetes and ovarian cancer.关键词
二甲双胍/2 型糖尿病/卵巢癌/发病风险/预后/Meta分析Key words
Metformin/Type 2 diabetes/Overian neoplasms/Risk/Prognosis/Meta analysis分类
医药卫生引用本文复制引用
谢辉,郑玉玲..二甲双胍与2型糖尿病患者卵巢癌风险及预后关系的meta分析[J].现代妇产科进展,2024,33(1):7-11,5.基金项目
全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]75号) （国中医药人教函[2022]75号）
全国名中医传承工作室建设项目(国中医药人教函[2022]245号) （国中医药人教函[2022]245号）
